Abstract:Objective To investigate the clinical efficacy and safety of sacubitril/valsartan in the treatment of refractory heart failure. Methods Fifty patients with refractory heart failure hospitalized from May 2018 to September 2019 were randomly divided into observation group and control group(n=25,each).The routine anti-heart failure drugs such as diuresis,cardiotonic drugs and angiotensin-converting enzyme inhibitors were given in control group,while oral sacubitril/valsartan was added on the basis of same routine treatment in observation group.After 14 days of treatment,the therapeutic effect,cardiac function indexes,serological indices and adverse reactions were compared between two groups. Results The total effective rate in observation group was significantly higher than that in control group(100.00% vs 76.00%,P<0.05).After treatment,the left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD),stroke volume (SV) and left ventricular ejection fraction (LVEF) were significantly improved compared with those before treatment in two groups (all P<0.01),and SV and LVEF were higher in observation group than those in control group,while LVESD and LVEDD were lower than those in control group (all P<0.01).Compared with those before treatment,the levels of N-terminal B-type natriuretic peptide precursor(NT-proBNP)and aldosterone(ALD) significantly decreased in both groups(all P<0.01)and were significantly lower in observation group than those in control group(all P<0.01).There was no statistical difference in the incidence of adverse reactions between observation group and control group(8.00% vs 20.00%,P>0.05). Conclusion Sacubitril/valsartan can effectively promote recovery of cardiac function and control heart failure in the treatment of refractory heart failure.